

해외 바이오의약품 임상 현황 (2021.3.8~2021.3.14)

한국바이오의약품협회, 2021.3.16.
출처: ClinicalTrials.gov

○ 미국 10건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04783090	MT1013 Clinical TRIAL In Healthy Subject	Healthy Volunteer	Drug: MT1013	Shaanxi Micot Technology Limited Company WCCT Global	Phase 1	_____
NCT04512287	PRP for Treatment of Peyronie's Disease	Peyronie Disease Sexual Dysfunction, Physiological Sexual Dysfunction Male Genital Diseases, Male	Drug: Autologous Platelet Rich Plasma Other: Saline Solution	University of Miami	Phase 2	_____
NCT04372927	ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy	Locally Advanced Lung Non-Small Cell Carcinoma Stage III Lung Cancer AJCC v8 Stage IIIA Lung Cancer AJCC v8 Stage IIIB Lung Cancer AJCC v8 Stage IIIC Lung Cancer AJCC v8	Drug: Cisplatin Biological: Durvalumab Drug: Etoposide Radiation: Hypofractionated Radiation Therapy Drug: Pemetrexed	University of Washington National Cancer Institute (NCI) AstraZeneca	Phase 2	_____
NCT04359784	Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy	B-Cell Non-Hodgkin Lymphoma	Biological: Anakinra Biological: Axicabtagene Ciloleuce	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) Sobi	Phase 2	_____
NCT04336943	Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load	Biochemically Recurrent Prostate Carcinoma Prostate Adenocarcinoma	Biological: Durvalumab Drug: Olaparib Other: Quality-of-Life Assessment Other: Questionnaire Administration	University of Washington National Cancer Institute (NCI) AstraZeneca	Phase 2	_____
NCT04013802	TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.	Viral Infection	Biological: HLA-matched VSTs	Baylor College of Medicine The Methodist Hospital System	Phase 1	_____
NCT04398680	A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Impaired Hepatic Function	Multiple Myeloma	Drug: Belantamab mafodotin	GlaxoSmithKline	Phase 1	_____
NCT04785144	Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults	COVID-19 COVID-19 Immunisation	Biological: mRNA-1273 Biological: mRNA-1273.351	National Institute of Allergy and Infectious Diseases (NIAID) ModernaTX, Inc.	Phase 1	_____
NCT04629248	A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy	Primary Membranous Nephropathy	Drug: Obinutuzumab Drug: Tacrolimus Drug: Methylprednisolone Drug: Acetaminophen Drug: Diphenhydramine	Hoffmann-La Roche	Phase 3	_____
NCT04792073	Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma	Merkel Cell Carcinoma	Drug: Avelumab Radiation: Comprehensive Ablative Radiation Therapy	Memorial Sloan Kettering Cancer Center EMD Serono	Phase 2	_____

○ 프랑스 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04629248	A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy	Primary Membranous Nephropathy	Drug: Obinutuzumab Drug: Tacrolimus Drug: Methylprednisolone Drug: Acetaminophen Drug: Diphenhydramine	Hoffmann-La Roche	Phase 3	_____

○ 독일 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04736134	A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants	Healthy Participants	Biological: BMS-986326 Other: Placebo matching BMS-986326	Bristol-Myers Squibb	Phase 1	_____

○ 중국 5건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04675983	A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)	Gastric Adenocarcinoma	Drug: Sintilimab Drug: Ramucirumab Drug: Cisplatin Drug: 5-fluorouracil Drug: Oxaliplatin Drug: Capecitabine	Innovent Biologics (Suzhou) Co. Ltd.	Phase 3	_____
NCT04694781	Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy	Cancer	Drug: LVGN6051 Drug: Pembrolizumab	Lyvgen Biopharma Holdings Limited	Phase 1	_____
NCT04783675	Efficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Nephrotic Syndrome	Steroid-Sensitive Nephrotic Syndrome	Drug: Rituximab	Children's Hospital of Fudan University Children's Hospital of Nanjing Medical University The Children's Hospital of Zhejiang University School of Medicine Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Wuhan Union Hospital, China Anhui Provincial Children's Hospital Shanghai Children's Hospital Children's Hospital Affiliated to Zhengzhou University Henan Children's Hospital	Phase 2	_____
NCT04654468	A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition	Paroxysmal Nocturnal Hemoglobinuria	Drug: Crovalimab	Hoffmann-La Roche	Phase 3	_____
NCT04629248	A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy	Primary Membranous Nephropathy	Drug: Obinutuzumab Drug: Tacrolimus Drug: Methylprednisolone Drug: Acetaminophen Drug: Diphenhydramine	Hoffmann-La Roche	Phase 3	_____

○ 일본 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	출처 URL
NCT04580407	Study of TAK-672 in Participants With Acquired Hemophilia A	Acquired Hemophilia A	Biological: TAK-672	Takeda	Phase 2 Phase 3	_____
NCT04760314	A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis	Dermatitis, Atopic Dermatitis Eczema Skin Diseases Skin Diseases, Genetic	Drug: Lebrikizumab Drug: Placebo Drug: Topical Corticosteroid	Eli Lilly and Company	Phase 3	_____